close Icon
  1. Home
  2. Knowledge and Media
  3. Research Articles
  4. Setting up pharmacovigilance based on available endTB Project data for bedaquiline.

Setting up pharmacovigilance based on available endTB Project data for bedaquiline.

Lachenal N, Hewison C, Mitnick C, Lomtadze N, Coutisson S, Osso E, Ahmed S, Leblanc G, Islam S, Atshemyan H, Nair P, Kholikulov B, Aiylchiev S, Zarli K, Adnan S, Krisnanda A, Padayachee S, Stambekova A, Sahabutdinova Y, de Guadalupe S, Moreno P, Kumsa A, Reshid A, Makaka J, Abebe S, Melikyan N, Seung KJ, Khan U, Khan P, Huerga H, Rich M, Varaine F

VIEW FULL ARTICLE

  • Journal The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

  • Published 27 Apr 2021

  • Volume 24

  • ISSUE 10

  • Pagination 1087-1094

  • DOI 10.5588/ijtld.20.0115

Abstract

Between 1 April 2015 and 31 March 2019, the PVU received and assessed 626 SAEs experienced by 417 BDQ patients. A board of MDR-TB/PV experts reviewed unexpected and possibly drug-related SAEs to detect safety signals. The experts communicated on clusters of risks factors, notably polypharmacy and off-label drug use, encouraging a patient-centred approach of care. Organising advanced PV in routine care is possible but demanding. It is reasonable to expect local/national programmes to focus on clinical management, and to limit reporting to aDSM systems to key data, such as the SAEs.